Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma

@inproceedings{Nozawa2012ContinuousOI,
  title={Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma},
  author={Masahiro Nozawa and Hirotsugu Uemura},
  booktitle={Translational andrology and urology},
  year={2012}
}
Sunitinib is globally approved for treatment of advanced renal cell carcinoma (RCC) at a dosage of 50 mg/day with four weeks on treatment and two weeks off, based on a randomized phase III trial in which its superiority over interferon alpha was established as first-line therapy for patients with metastatic RCC (1). On the other hand, continuous daily… CONTINUE READING